Ruti Aga: The Six-Year Ban Is About Route and Timing, Not 'Steroids'

“Two years for presence. Four for tampering. Total: six.” In Ruti Aga’s case, that arithmetic looks like a routine sanction ledger. It is actually the skeleton of the story. The 32-year-old Ethiopian marathoner has been banned for six years by the Athletics Integrity Unit (AIU) after a sample taken at a half marathon she won in China in March tested positive for methylprednisolone, and after she submitted a forged prescription. The headline says doping. The substance says otherwise. The case turns on drug classification, the in-competition testing window, and document verification. According to the AIU statement, Aga cited a knee injury. The prescription was written by a family member who presented himself as a doctor; the clinic named on the document did not exist; and the man said he had used “an old prescription pad from a former workplace,” which the clinic explicitly disowned. Three separate verification failures. For me, this is not just a bad document. It is the signature of an athlete operating without a credentialed team physician. Many reports called methylprednisolone a “prohibited steroid.” That is imprecise. On the WADA Prohibited List, it is an S9 glucocorticoid, not an S1 anabolic steroid. S9 drugs are prohibited in-competition only, by injection, oral or rectal routes. Intra-articular or peri-articular methylprednisolone for knee synovitis is standard sports-medicine practice in distance runners. An injection given out-of-competition is not automatically a violation; it becomes one if residues are present in-competition or if the medical record does not support a legitimate therapeutic use. The case hinged on route, timing and paperwork, not on “steroid use.” The spreadsheet remembers what the crowd forgets. Two years for the presence violation and four for tampering is consistent with the standard architecture of the World Athletics Anti-Doping Rules and the WADA Code. The two-year presence sanction suggests the panel treated it as a Specified Substance case without proven intent, but refused the no-significant-fault mitigation. The four-year tampering sanction was added separately, because a forged prescription is an attempt to mislead the evidence chain. In sports law, that second offence carries its own weight. The near-paradox: forged documentation is itself circumstantial evidence of concealment intent, yet it did not escalate the presence sanction; it added a separate sentence. The report does not state whether Aga’s March half-marathon result and prize money will be annulled. Standard AIU practice is to disqualify the competition where the sample was collected, so the result and ranking points from that race should be treated as void. But the 2026 Tokyo Marathon title and three World Marathon Majors second places do not automatically disappear. Annulling results before March would require a separate finding of earlier use, which this report does not provide. That distinction matters: an athlete’s historical record and an athlete’s current availability are sliced into different parts of the same decision. The Chinese label-race circuit is the other silent party here. It is a lucrative, low-risk income tier for East African marathoners between Majors, and it is now one of the AIU’s highest-yield testing grounds. The appearance-fee economy and the testing economy are colliding in the same races. The in-competition testing window opens at 23:59 the day before the race, so a glucocorticoid injection given days earlier can be caught. At 32, a six-year ban is not simply six years. The report does not give the year attached to the 10 September start date, but the arithmetic is clear: she would return at roughly 38. In Ethiopian women’s marathon depth, a 2:18–2:20 performer is not automatically selectable; a 38-year-old returning with a doping record is effectively unselectable. Based on my years of watching road-running cases, the more useful question than the length of a ban is whether the athlete has a route back. Here, the route looks closed. The autopsy began at 2 a.m., and it was never about blame. It was about how a knee injury, a forged prescription and an informal medical network fit together. The counter-intuitive part is that six years is not being imposed for a drug that clearly boosts marathon performance. There is no solid evidence that glucocorticoids improve endurance; they reduce pain and inflammation, which can keep an injured runner on the start line. The real violation is the document. That is why the case will be cited both as proof of AIU rigour and as evidence of disproportionate enforcement against African road runners. Both readings need the same fact: the route-and-timing record. The record that did not exist became the sentence. The next signal will come in the AIU’s reasoned decision: the date of the injection, the gap to competition, the TUE status, and the scope of disqualification. If more cases from the same training cluster produce forged prescriptions, this is not a story of individual corruption. It is a system’s document-verification crisis. When the crowd left, the experiment I was never allowed to run began: an injured marathoner, a family “doctor” in a room, and a drug that became a violation only because of timing. The question is not why the ban is six years. The question is whether a correct medical file six months earlier would have prevented the case from existing at all.